Lotrisone: Dual-Action Relief for Fungal and Inflammatory Skin Conditions
| Product dosage: 10 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 5 | $8.27 | $41.34 (0%) | 🛒 Add to cart |
| 6 | $7.56 | $49.61 $45.38 (9%) | 🛒 Add to cart |
| 7 | $7.06 | $57.88 $49.41 (15%) | 🛒 Add to cart |
| 8 | $6.68 | $66.15 $53.44 (19%) | 🛒 Add to cart |
| 9 | $6.39 | $74.42 $57.48 (23%) | 🛒 Add to cart |
| 10 | $6.15
Best per tube | $82.69 $61.51 (26%) | 🛒 Add to cart |
| Product dosage: 20 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 2 | $21.18 | $42.35 (0%) | 🛒 Add to cart |
| 4 | $18.40 | $84.70 $73.61 (13%) | 🛒 Add to cart |
| 8 | $16.76 | $169.41 $134.11 (21%) | 🛒 Add to cart |
| 16 | $16.01
Best per tube | $338.81 $256.12 (24%) | 🛒 Add to cart |
Synonyms | |||
Lotrisone is a prescription-only combination topical medication containing two active pharmaceutical ingredients: clotrimazole, a broad-spectrum antifungal agent, and betamethasone dipropionate, a potent corticosteroid. This synergistic formulation is specifically engineered to treat dermatological conditions where both fungal infection and inflammatory response are present, providing comprehensive therapeutic management. It is indicated for the treatment of various tinea infections and certain cutaneous candidiasis, offering both antimicrobial and anti-inflammatory efficacy in a single application. Its use is reserved for cases where corticosteroid treatment is warranted alongside antifungal therapy, as determined by a healthcare professional.
Features
- Contains clotrimazole 1% and betamethasone dipropionate 0.05% in a refined cream or lotion base
- Exhibits both fungistatic and fungicidal activity against dermatophytes and yeasts
- Provides potent anti-inflammatory, antipruritic, and vasoconstrictive effects
- Formulated for optimal cutaneous penetration and patient compliance
- Available in 15g and 45g tubes for precise dosing and treatment duration control
Benefits
- Effectively eliminates pathogenic fungi while simultaneously reducing associated inflammation, redness, and itching
- Accelerates symptomatic relief, improving patient comfort and quality of life during treatment
- Reduces the risk of secondary bacterial infections by controlling excoriation and skin breakdown
- Minimizes treatment complexity through a unified therapeutic approach instead of multiple products
- Helps prevent recurrence by addressing both the infectious agent and the inflammatory environment it creates
- Supports adherence through convenient twice-daily application and generally well-tolerated formulation
Common use
Lotrisone is primarily prescribed for the treatment of tinea corporis (ringworm of the body), tinea cruris (jock itch), and tinea pedis (athlete’s foot) caused by susceptible organisms such as Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. It is also indicated for cutaneous candidiasis. The medication is particularly valuable in cases where significant inflammation, erythema, or pruritus accompanies the fungal infection. Diagnosis should be confirmed by potassium hydroxide (KOH) preparation or culture to ensure appropriate use, as corticosteroids are contraindicated in certain fungal infections without proper antifungal coverage.
Dosage and direction
Apply a thin layer of Lotrisone to the affected skin area twice daily, in the morning and evening. Gently massage into the cleansed, dry skin until absorbed. Wash hands before and after application unless treating hands. Treatment duration for tinea corporis and tinea cruris should generally not exceed two weeks; for tinea pedis, use should not exceed four weeks. Do not use occlusive dressings unless directed by a physician, as this may increase systemic absorption of the corticosteroid component. Use exactly as prescribed; do not exceed recommended frequency or duration.
Precautions
Use Lotrisone with caution in pediatric patients, as children may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome. Avoid application to the face, groin, or axillae unless directed by a physician. Discontinue if irritation develops. Do not use for longer than prescribed period to avoid potential skin atrophy, striae, or telangiectasias. Patients should be advised that this medication is for external use only and should not be used for ophthalmic, oral, or intravaginal administration. Monitor for signs of secondary infection.
Contraindications
Lotrisone is contraindicated in patients with known hypersensitivity to clotrimazole, betamethasone, other imidazoles, or corticosteroids. Should not be used for primary bacterial infections (impetigo, cellulitis), viral infections (herpes simplex, varicella), or tuberculous, syphilitic, or vaccinia lesions. Contraindicated in rosacea, perioral dermatitis, and acne vulgaris. Not recommended for use under occlusive dressings in large areas, broken skin, or in patients with circulatory disorders. Avoid in pregnancy unless potential benefit justifies potential risk to fetus.
Possible side effect
Common local reactions may include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, and hypopigmentation. With prolonged use or application to large body surface areas, systemic effects may occur including hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria. Allergic contact dermatitis may develop. Secondary infection may occur. Rare reports of striae, skin atrophy, and miliaria have been documented with corticosteroid use.
Drug interaction
No specific drug interactions have been formally documented with topical Lotrisone. However, systemic absorption of corticosteroids may potentially interact with other medications, particularly in cases of excessive use or application to large surface areas. Theoretical interactions include reduced efficacy of antidiabetic medications, potentiation of hypokalemia with potassium-depleting diuretics, and possible interactions with CYP3A4 inhibitors. Inform your physician of all medications, including prescription, over-the-counter, and herbal products.
Missed dose
Apply the missed dose as soon as remembered, unless it is almost time for the next scheduled application. Do not apply extra medication to make up for a missed dose. Maintain the regular application schedule; do not double the dose. If uncertain about missed dose management, consult your healthcare provider or pharmacist for guidance specific to your treatment regimen.
Overdose
Topically applied Lotrisone can lead to systemic effects if applied excessively or over large body surface areas, particularly under occlusive dressings. Symptoms may include steroid-related effects such as hypercorticism, adrenal suppression, fluid retention, hypertension, hypokalemia, and hyperglycemia. Treatment involves discontinuation of the medication, symptomatic management, and appropriate supportive care. In case of accidental ingestion, seek immediate medical attention as corticosteroid overdose may require medical intervention.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Do not freeze. Keep tube tightly closed when not in use. Protect from light and excessive heat. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly discard any unused medication after treatment completion or expiration.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lotrisone is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Always follow your physician’s instructions regarding medication use, dosage, and treatment duration. Do not self-diagnose or self-medicate. Consult your healthcare provider for proper diagnosis and treatment recommendations specific to your medical condition.
Reviews
Clinical studies demonstrate Lotrisone’s efficacy in treating dermatophytoses with associated inflammation. In comparative trials, the combination product showed superior results in reducing signs and symptoms compared to antifungal monotherapy. Patients report significant improvement in pruritus and erythema within the first week of treatment. Dermatologists note its particular value in cases where inflammation complicates fungal infections. However, experts emphasize the importance of appropriate patient selection and limited duration of use to minimize potential corticosteroid-related adverse effects.